Savion Gropper
Overview
Explore the profile of Savion Gropper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
629
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Halton J, Picard A, Harper R, Huang F, Brueckmann M, Gropper S, et al.
Thromb Haemost
. 2017 Dec;
117(11):2168-2175.
PMID: 29202215
Venous thromboembolism (VTE) is more frequent in infants than in older children. Treatment guidelines in children are adapted from adult VTE data, but do not currently include direct oral anticoagulant...
12.
Cannon C, Bhatt D, Oldgren J, Lip G, Ellis S, Kimura T, et al.
N Engl J Med
. 2017 Aug;
377(16):1513-1524.
PMID: 28844193
Background: Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy is associated...
13.
Cannon C, Gropper S, Bhatt D, Ellis S, Kimura T, Lip G, et al.
Clin Cardiol
. 2016 Aug;
39(10):555-564.
PMID: 27565018
Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet therapy for prevention of stent...
14.
Anker S, Schroeder S, Atar D, Bax J, Ceconi C, Cowie M, et al.
Eur J Heart Fail
. 2016 Jun;
18(6):727.
PMID: 27324688
No abstract available.
15.
Anker S, Schroeder S, Atar D, Bax J, Ceconi C, Cowie M, et al.
Eur J Heart Fail
. 2016 Apr;
18(5):482-9.
PMID: 27071916
Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical...
16.
Gropper S, Albareda N, Chelius K, Kruger D, Mitha I, Vahed Y, et al.
Future Microbiol
. 2014 Oct;
9(9):1013-23.
PMID: 25340832
Aim: We compared the efficacy and safety of ozenoxacin (a new nonfluorinated quinolone) 1% cream with placebo in the treatment of impetigo. Patients & Methods: In a randomized, double-blind, multicenter...
17.
Gropper S, Cepero A, Santos B, Kruger D
Future Microbiol
. 2014 Sep;
9(8 Suppl):S33-40.
PMID: 25209523
In this Phase I open-label study, the systemic absorption, clinical response, safety and tolerability of multiple-dose ozenoxacin 1% cream were evaluated in children (≥ 2 months of age) and adults...
18.
Santos B, Ortiz J, Gropper S
Future Microbiol
. 2014 Sep;
9(8 Suppl):S3-9.
PMID: 25209522
In vitro studies using excised human skin samples were conducted to evaluate the percutaneous absorption and skin metabolism of ozenoxacin. The formulations studied were 1% ointment, 1% cream and 2%...
19.
Gropper S, Cepero A, Dosik J, LaStella P, Siemetzki H, Wigger-Alberti W
Future Microbiol
. 2014 Sep;
9(8 Suppl):S23-31.
PMID: 25209521
In this series of Phase I, randomized, placebo-controlled studies in healthy volunteers, the potential for ozenoxacin 1 and 2% cream formulations to cause irritation, sensitization, phototoxicity and photoallergy under occlusive...
20.
Gropper S, Albareda N, Santos B, Febbraro S
Future Microbiol
. 2014 Sep;
9(8 Suppl):S17-22.
PMID: 25209520
In this Phase I study, healthy volunteers (n = 24) were randomly allocated to receive either one or two 0.2-g applications per day (12 h apart) of ozenoxacin 2% cream...